Response assessment in clinical trials: implications for sarcoma clinical trial design

Area of Science:

• Oncology
• Radiology
• Clinical Trial Design

Background:

• Validated response criteria are essential for anticancer drug approval.
• Current anatomic imaging criteria are challenging for evaluating certain tumors like soft tissue sarcomas.
• New molecular imaging modalities offer complementary data to conventional methods.

Purpose of the Study:

• To review current and emerging approaches in clinical trial design for sarcomas.
• To address the limitations of existing response criteria in sarcoma evaluation.
• To inform the optimization of clinical development and therapeutic evaluation for sarcomas.

Main Methods:

• Review of existing anatomic imaging criteria for tumor response assessment.
• Exploration of novel molecular imaging techniques (e.g., 64-slice CT, dynamic contrast MRI).
• Analysis of ongoing efforts by regulatory bodies to revise response criteria.

Main Results:

• Anatomic imaging criteria face limitations in evaluating specific tumor types, including soft tissue sarcomas.
• Advanced imaging techniques provide valuable supplementary information.
• Regulatory agencies are working towards updating criteria using volumetric imaging.

Conclusions:

• Revised response criteria incorporating advanced imaging are needed for sarcoma clinical trials.
• Optimizing clinical trial design is key to advancing sarcoma therapy.
• Improved evaluation methods will facilitate the development and approval of new anticancer agents for sarcomas.